NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease
| العنوان: | NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease |
|---|---|
| المؤلفون: | Agnieszka Kolasińska-Ćwikła, Damian Czyżewski, Matteo Roffinella, Alejandro L Suarez, Mateusz Rydel, Monika Wójcik-Giertuga, Anna Malczewska, Dariusz Ziora, Agata Walter, Beata Kos-Kudła, Jarosław B. Ćwikła, Izabela Zielińska-Leś, Priya A. Jamidar, Lisa Bodei, Kjell Öberg, Anna Lewczuk, Harry R. Aslanian, Pier Luigi Filosso |
| المصدر: | Neuroendocrinology. 108:219-231 |
| بيانات النشر: | S. Karger AG, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, Lung Neoplasms, Endocrinology, Diabetes and Metabolism, Neuroendocrine tumors, Gastroenterology, 030218 nuclear medicine & medical imaging, Idiopathic pulmonary fibrosis, 0302 clinical medicine, Endocrinology, Biomarker, Blood, Bronchopulmonary carcinoid, Lung cancer, NETest, Neuroendocrine tumor, PCR, Transcript Progression, Adult, Aged, 80 and over, Case-Control Studies, Disease Progression, Female, Humans, Liquid Biopsy, Middle Aged, Neuroendocrine Tumors, Sensitivity and Specificity, Young Adult, Aged, 80 and over, medicine.anatomical_structure, Biomarker (medicine), medicine.medical_specialty, 030209 endocrinology & metabolism, 03 medical and health sciences, Cellular and Molecular Neuroscience, Internal medicine, medicine, Liquid biopsy, Lung, Endocrine and Autonomic Systems, business.industry, Histology, medicine.disease, business, Progressive disease |
| الوصف: | Background: There are no effective biomarkers for the management of bronchopulmonary carcinoids (BPC). We examined the utility of a neuroendocrine multigene transcript “liquid biopsy” (NETest) in BPC for diagnosis and monitoring of the disease status. Aim: To independently validate the utility of the NETest in diagnosis and management of BPC in a multicenter, multinational, blinded study. Material and Methods: The study cohorts assessed were BPC (n = 99), healthy controls (n = 102), other lung neoplasia (n = 101) including adenocarcinomas (ACC) (n = 41), squamous cell carcinomas (SCC) (n = 37), small-cell lung cancer (SCLC) (n = 16), large-cell neuroendocrine carcinoma (LCNEC) (n = 7), and idiopathic pulmonary fibrosis (IPF) (n = 50). BPC were histologically classified as typical (TC) (n = 62) and atypical carcinoids (AC) (n = 37). BPC disease status determination was based on imaging and RECIST 1.1. NETest diagnostic metrics and disease status accuracy were evaluated. The upper limit of normal (NETest) was 20. Twenty matched tissue-blood pairs were also evaluated. Data are means ± SD. Results: NETest levels were significantly increased in BPC (45 ± 25) versus controls (9 ± 8; p < 0.0001). The area under the ROC curve was 0.96 ± 0.01. Accuracy, sensitivity, and specificity were: 92, 84, and 100%. NETest was also elevated in SCLC (42 ± 32) and LCNEC (28 ± 7). NETest accurately distinguished progressive (61 ± 26) from stable disease (35.5 ± 18; p < 0.0001). In BPC, NETest levels were elevated in metastatic disease irrespective of histology (AC: p < 0.02; TC: p = 0.0006). In nonendocrine lung cancers, ACC (18 ± 21) and SCC (12 ± 11) and benign disease (IPF) (18 ± 25) levels were significantly lower compared to BPC level (p < 0.001). Significant correlations were evident between paired tumor and blood samples for BPC (R: 0.83, p < 0.0001) and SCLC (R: 0.68) but not for SCC and ACC (R: 0.25–0.31). Conclusions: Elevated NETest levels are indicative of lung neuroendocrine neoplasia. NETest levels correlate with tumor tissue and imaging and accurately define clinical progression. |
| تدمد: | 1423-0194 0028-3835 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5fd16228a86e3c0081271a834dbb3a https://doi.org/10.1159/000497037 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....1f5fd16228a86e3c0081271a834dbb3a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14230194 00283835 |
|---|